Caplin Point Board Approves Q1 FY27 Results, Recommends Final Dividend, Reappoints MD
Caplin Point Laboratories reported Q1 FY27 consolidated revenue of ₹643.91 Crores (up 20.7% YoY) and PAT of ₹179.09 Crores (up 18.8% YoY). The Board recommended a final dividend of ₹4 per share. Dr. Sridhar Ganesan was re-appointed MD, and Mr. D. Muralidharan was appointed Whole-Time Director. The AGM is on September 25, 2026.
The announcement includes financial results, dividend declaration, and significant management changes, all of which are material information for investors and stakeholders.
The company reported strong year-on-year growth in revenue and profit, recommended a final dividend, and approved key management re-appointments and appointments, all positive indicators for stakeholders.
Caplin Point Laboratories Limited announced the outcome of its Board Meeting held on August 12, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the Limited Review Report and a press release. The company reported a total consolidated revenue of ₹643.91 Crores for the quarter, an increase of 20.7% year-on-year, and a Profit After Tax (PAT) of ₹179.09 Crores, up 18.8% year-on-year. The Board recommended a Final Dividend of ₹4/- (200%) per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The dividend, if approved, will be paid on or before October 24, 2026. Additionally, the Board approved the re-appointment of Dr. Sridhar Ganesan as the Managing Director for a further period of two years, effective August 25, 2026, and the appointment of Mr. D. Muralidharan as the Whole-Time Director for two years, effective August 12, 2026. The 35th AGM is scheduled for Friday, September 25, 2026, to be conducted via Video Conferencing/Other Audio-Visual means.
What to do with a filing like this
Caplin Point Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Caplin Point Laboratories Limited. Read the original for the full detail.